Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UIO-S26
- Development stage
- Preclinical
- Lead developer
- TransCode Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
UIO-S26 is a preclinical RNA therapy candidate being developed by TransCode Therapeutics for the treatment of colorectal liver metastasis. The drug candidate was part of the portfolio associated with Polynoma LLC, which was acquired by TransCode Therapeutics. UIO-S26 is part of a broader series of RNA-based therapeutics (including UIO-S24 and UIO-S25) resulting from collaborations, such as those with the University of Oslo. While the specific molecular target and mechanism of action for UIO-S26 have not been publicly disclosed in company pipeline documentation, it is designed to address metastatic disease in the liver originating from colorectal cancer.
Beyond the preview
Go deeper on UIO-S26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UIO-S26.